ITCI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 1890 min ago

@ $69.21

Wydano: 3 geg. 2024 @ 19:37

Zwrot: -0.59%

Poprzedni sygnał: geg. 2 - 22:49

Poprzedni sygnał: Sprzedaż

Zwrot: -2.38 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	892 882
Średni wolumen	974 238
Kapitalizacja rynkowa	6.66B
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $0 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-47.12
ATR14	$2.85 (4.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Mates Sharon	Buy	11 382	Common Stock
2024-04-24	Mates Sharon	Buy	8 638	Common Stock
2024-04-24	Mates Sharon	Sell	11 382	Stock Option (right to buy)
2024-04-24	Mates Sharon	Sell	8 638	Stock Option (right to buy)
2024-03-31	Van Nostrand Robert L	Buy	79	Common Stock

INSIDER POWER
1.82
Last 100 transactions
Buy: 523 032 \| Sell: 503 157

Wolumen Korelacja

Długi: -0.33 (neutral)

Krótki: -0.40 (neutral)

Signal:(52) Neutral

Intra-Cellular Therapies Korelacja

10 Najbardziej pozytywne korelacje
BOCH	0.927
SHSP	0.882
BLRX	0.862
SOVO	0.851
DBDR	0.84
MMAC	0.838
GWAC	0.833
SCYX	0.825
FCAC	0.823
TLSA	0.823

10 Najbardziej negatywne korelacje
GAINL	-0.944
APOP	-0.87
RMRM	-0.867
TDAC	-0.855
ISNS	-0.852
FNWD	-0.85
CLDX	-0.836
MNDO	-0.835
SVOK	-0.835
AGIL	-0.83

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intra-Cellular Therapies Korelacja - Waluta/Towar

-0.69
( moderate negative )

-0.61
( weak negative )

0.00
( neutral )

-0.65
( moderate negative )

-0.63
( weak negative )

0.27
( neutral )

Intra-Cellular Therapies Finanse

Annual	2023
Przychody:	$462.18M
Zysk brutto:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2023
Przychody:	$462.18M
Zysk brutto:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2022
Przychody:	$249.13M
Zysk brutto:	$228.69M (91.79 %)
EPS:	$-2.72

FY	2021
Przychody:	$83.80M
Zysk brutto:	$75.77M (90.41 %)
EPS:	$-3.50

Financial Reports:

No articles found.

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.